ASCVD drives major global health and economic burden, with LDL-C responsible for up to one-third. Better prevention and management could reduce costs and save lives.

This is the second in a series of blogs about how the proposals in the recently published 10 Year Plan measure up against some of the most pressing health concerns in the UK.

When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wan...

The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA fr...

Long-acting therapies offer value for chronic disease, improving adherence and outcomes. This OHE report highlights HTA gaps, real-world evidence, and policy needs.

The Respiratory Cost Calculator summarises the potential financial impacts of employee absenteeism and presenteeism as incurred by the employer due to respiratory infections.

This report explores the variation in past and current positioning of Health Technology Assessment (HTA) agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient...